in the next 3 years, every major AI lab will spin up its own bio arm and in-house wet labs.
biology is the next big bet in AI after code
pay attention.
1/
CHAMPION-AF: When is a 'win' not a win?
When noninferior efficacy isn’t established using stringent relative margin.
When superior safety is not established using unbiased procedural & nonprocedural bleeding patients care about.
Finally, when ischemic stroke risk is ⬆️ 61%.
My son died. I know he didn't contribute anything to mankind — he was only two months old — but I like to believe he was destined to do something good for humanity. It's been a while since his death, and I hate to dwell on it so publicly, but I wanted you to know him.
Couple interesting meetings for FDA Commissioner Makary: met with Arnold Ventures on Mar. 3 about "collaboration opportunities" https://t.co/vEyhDu5xaW
and with $MNPR on "establishing a regulatory mechanism" on Mar. 13 https://t.co/DHaD6IlvCS
A reminder worth noting today.
For both the receptor (ACVR1C gene encoding ALK7, discovery 2019) and the ligand (INHBE gene encoding Activin E, discovery 2022):
NO association of human genetic variation with overall BMI
but
rather the distribution of weight across compartments (visceral vs not) as well as cardiometabolic diseases
I've traded futures markets for five decades. There is ZERO doubt in my mind that Trump money was behind this buying.
There is NOOOOO law that prevents the Trump machine from manipulating futures markets. Inside trading is legal
Trump family fortune grew today. Trump is playing markets like a fiddle
Are you ready to shape the future of public health at the highest levels?
The FDA is seeking an exceptional executive leader to serve as the Center Director for CBER—a role at the forefront of regulating life-saving biological products, vaccines, and emerging therapies.
This is an opportunity to protect and advance public health on a national scale. You'll work on cutting-edge science, shape critical regulatory policy, and lead a team dedicated to ensuring the safety and effectiveness of biological products that save lives.
Apply by April 3, 2026. #FDAJobs
https://t.co/9muGQAAhqr
Med Students yesterday:
"After 10 years, including a gap year and 2 years in a non ACGME accredited fellowship, I'm pleased to announce I've matched in Neurosurgery. Happy to serve."
Van Nuys Home Health Care operators:
"Lulz. Let me show you my new Maybach"
One of the most meaningful evolutions in the 2026 ACC/AHA dyslipidemia guideline is the continued elevation of CAC as a central tool in preventive decision-making.
We have come a long way.
1. In the 2013 guidelines, CAC was effectively sidelined.
2. By 2019, it re-emerged as a decision aid.
3. In 2026, it is now clearly embedded in the framework of risk assessment, treatment initiation, and treatment intensity.
Two messages stand out.
1. First, CAC has become the preferred decision aid when treatment decisions are uncertain. This is not an uncommon situation. In real-world practice, uncertainty is the rule rather than the exception, especially in borderline or intermediate-risk individuals. #PowerOfZero provides a clear distinction who is and not at risk that for the decision whether lipid-lowering therapy should be initiated.
2. Second, the guideline goes beyond initiation. CAC is increasingly used to guide the intensity of therapy. Increasing plaque burden corresponds to progressively more aggressive LDL targets and therapeutic strategies. For example, individuals with CAC ≥300–1000 are recommended to pursue LDL reduction strategies approaching secondary prevention intensity, reflecting event rates comparable to treated ASCVD populations.
This is a MAJOR shift.
CAC is no longer simply a tie-breaker for statin decisions. It is evolving into a disease-guided framework for preventive intensity.
From a practical standpoint, this matters.Risk equations estimate probability. CAC visualizes disease.
1. When uncertainty exists, seeing the burden of atherosclerosis often changes the conversation for both clinician and patient.
2. It also aligns therapy more closely with biology (GREATER DISEASE, MORE INTENSE THE TREATMENT) rather than risk-factor projections alone.
IN 2026. CAC has moved from the margins of guidelines to the center of preventive cardiology.
For clinicians, that represents one of the most practical advances in translating risk assessment into actionable care.
Congrats @rblument1@RonBlankstein@DrMichaelShapir & rest of the guideline authors
@AJPCardio@ASPCardio@MichaelJBlaha@Sadeer_AlKindi@HMethodistCV
A video shows a patient with Dravet syndrome performing activities of daily living before and after treatment with zorevunersen.
Watch the full video and read the full report: https://t.co/Tm1VSETt15
This 'senior official' was Vinay Prasad. Disclosing trade secret information without legal authorization is a prohibited act under the FDCA & a criminal violation under the Trade Secrets Act.
A 22-year-old popped a pimple on her nose.
A week later she ended up in hospital with septic pulmonary emboli and cavernous sinus thrombosis.
The triangle of death is not a myth. Never pop pimples there.
I saw a case like this once. Will never forget it.
When a phase 1 trial is published in @NEJM, you can bet it will be impactful. Here, the p53 reactivator rezatapopt showed an ORR 20% among 77 pts with TP53 mutant (Y220C) advanced tumors. Are we getting closer to drug the most undruggable of all mutations? https://t.co/lpkvWiNNmu
Aspirin is safer and more effective than Viagra for treating ED
500mg mixed in hot water and baking soda, It lowers inflammation, improves blood flow, increases carbon dioxide which is the optimal vasodilator, and allow your gonads to oxidise glucose which they need in order to maintain strong erection.
The baking soda will lower lactate which makes your blood viscous, lactate also lowers carbon dioxide and cause vasoconstriction.